Leading the Charge

We’ve built a company poised to produce transformative pharmaceutical solutions by bringing together leaders steeped in all the functional areas needed to bring new drugs to life. With a deeply skilled management team directing our day-to-day wins, and a Board with a stellar track record, we’re acquiring, developing and commercializing drug candidates for diseases where there is a high unmet medical need.

The Backbone of our Innovation

The Dova Board brings impressive experience to the table, bright minds from across the spectrum of relevant disciplines helping to illuminate the path forward for our pharmaceutical solutions.

Alex C. Sapir

Alex C. Sapir

Joined Dova Board: January 2017

Mr. Sapir served as Dova’s President and Chief Executive Officer from January 2017 to December 2018. From January 2006 to May 2016, he served as Executive Vice President, Marketing and Sales for United Therapeutics Corporation, a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life threatening conditions. Prior to that, Mr. Sapir was a consultant with ZS Associates. Mr. Sapir began his pharmaceutical career at GlaxoSmithKline where he served in a variety of commercial roles in both the United States. and Europe. Mr. Sapir is a routine guest lecturer on the topic of pharmaceutical marketing strategy at Duke University’s Fuqua School of Business. He received his B.A. in Economics from Franklin and Marshall College and his M.B.A. from Harvard Business School.